secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inspire Medical Systems, Inc. (INSP)
CIK:        0001609550
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001609550-24-000042
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inspire Q2 revenue $195.9M (+30% YoY), EPS $0.32; raises FY guide, authorizes $150M buyback
--------------------------------------------------------------------------------

- Q2 revenue $195.9M (30% YoY), net income $9.8M vs loss $12.0M; diluted EPS $0.32 vs ($0.41).
- FY 2024 revenue guidance raised to $788-798M (26-28% growth); EPS guidance raised to $0.60-0.80 from $0.10-0.20.
- Board authorized $150M share repurchase program, first in company history, expiring August 5, 2026.
- Received FDA approval for Inspire V neurostimulation system and EU MDR CE Mark for full-body MRI compatibility.
- Activated 81 new U.S. centers in Q2 (total 1,316) and added 12 sales territories (total 310).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609550/000160955024000042/0001609550-24-000042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609550/000160955024000042/insp-20240806.htm
  HTML page:      https://secwatch.observer/filing/0001609550-24-000042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer